Skip to content

Effects of Dan-Lou Tablet for Coronary Heart Disease Stable Angina Pectoris with Intermingled Phlegm and Blood Stasis Pattern: A Randomized, Double-blinded, Parallel Placebo controlled Trial

Effects of Danlou Tablet for the treatment of stable angina pectoris: a study protocol of a randomized, double-blind, and placebo-controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002839
Enrollment
Unknown
Registered
2019-12-09
Start date
2020-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease stable angina pectoris

Interventions

Sponsors

Guang'anmen Hospital,Chinese Academy of Traditiona Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Conform to the diagnosis of coronary heart disease stable angina pectoris with intermingled phlegm and blood stasis Pattern; 2. Between the ages of 30 and 75 years; 3. Volunteer for this event and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Unstable angina pectoris and acute myocardial infarction; other congenital heart disease, valvular disease, severe neurosis caused by chest pain; heart function of grade III or IV; chest pain caused by arrhythmia; 2. Acute stage of cerebral infarction; 3. Complicated with heart, brain, liver, kidney, hematopoietic system and other serious primary diseases abnormal renal function; 4. Acute infection within the last two weeks; 5. Patients with other serious diseases that require treatment; 6. Mental disorders or mental retardation that cannot complete the questionnaire; 7. Pregnant and lactating women; 8. Tendency to bleed, abnormal of DIC or INR, low platelet; 9. Patients who did not participate in other clinical trials within 1 month; 10. Allergic constitution or allergic to test drug ingredient.

Design outcomes

Primary

MeasureTime frame
Frequency of angina pectoris attack;Outcome of safety;

Secondary

MeasureTime frame
Duration of angina pectoris attack;Efficacy evaluation criteria for coronary heart disease angina pectoris with traditional chinese medicine treatment;Change of blood lipid;Efficacy of electrocardiograph;Reduction rate of rescue drug ;

Countries

China

Contacts

Public ContactWang Jie

Guang'anmen Hospital, Chinese Academy of Traditional Chinese medicine

wangjie0103@126.com+86 17888808584

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026